NDANASALSPRAY, METERED
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
TRUDHESA (dihydroergotamine mesylate) by Baxter is clinical pharmacology mechanism of action dihydroergotamine binds with high affinity to 5-ht 1dα and 5-ht 1dβ receptors. Approved for migraine. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUDHESA is a nasal spray formulation of dihydroergotamine mesylate approved in 2021 for acute migraine treatment. It works by binding to serotonin 5-HT1D receptors on intracranial blood vessels and trigeminal nerve endings, causing vasoconstriction and inhibiting pro-inflammatory neuropeptide release. The drug represents a non-oral alternative for migraine rescue therapy with a well-established mechanism of action.
$0.003BPart D
Peak12.7 years to LOETRUDHESA is in peak lifecycle phase but commands minimal Part D spending ($3M in 2023) relative to competitors, suggesting limited market penetration and a smaller commercial team footprint.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. It also binds with high affinity to serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors, noradrenaline α 2A , α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The…
Worked on TRUDHESA at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.